UVA-1 phototherapy produced parallel gains in skin scores and patient-reported symptoms
A small pilot study from the University of Utah adds clinical texture to a therapy that has long been discussed but not well measured in sclerosing skin disease. After 30 UVA-1 sessions over a 100-day period, patients with morphea, systemic sclerosis, and sclerotic chronic cutaneous graft-versus-host disease showed improvement in several patient-reported and clinician-reported outcomes, while measures of fixed damage were far less responsive.
Seventeen adults completed the treatment course. Most were women, the mean age was 47.2 years, and the cohort included eight patients with morphea, eight with limited or diffuse cutaneous systemic sclerosis, and one patient with sclerotic chronic cutaneous GVHD. Sessions delivered 50 to 90 J/cm2 per treatment, with an average frequency of two to three visits each week. Concomitant therapies were not stopped; the regimen included mycophenolate mofetil, hydroxychloroquine, prednisone, rituximab, and topical steroids. In a disease group this small and biologically mixed, that background treatment matters because it limits how cleanly any single intervention can be isolated.
Symptom relief emerged before disability measures moved
The most clinically meaningful signal appeared in skin-related quality of life. Skindex-16 improved in all three reported domains: emotional, symptoms, and functioning. The symptom domain showed the largest change, falling by 28.6 points, while emotional burden dropped by 16.2 points and functioning by 9.1 points. PROMIS Physical Functioning also improved slightly, rising by 2.12 points.
One measure did not move with the same clarity. HAQ-DI did not reach statistical significance, and the pain scale showed only a borderline trend toward improvement. The average HAQ-DI change was essentially flat, moving from 2.22 to 2.24. In practical terms, that pattern suggests that a therapy can reduce skin tightness, itch, emotional strain, and subjective symptom burden without yet reversing the functional limitations that patients experience in daily life.
Objective skin thickening also moved in the expected direction
Clinician-rated assessments tracked with the patient-reported improvements. The modified Rodnan Skin Score fell by 7.5 points in the systemic sclerosis subgroup, while the Hand Mobility in Scleroderma score improved on both sides. Morphea activity also dropped sharply: the Localized Scleroderma Activity Index improved by 17.9 points, and Physician Global Assessment of activity declined by 35.1 points. These shifts fit the biology of UVA-1 therapy, which is thought to act on inflammatory and fibrotic pathways in the skin rather than on irreversible architectural damage alone.
A single result stood apart. Damage-related measures did not improve. PGA Damage and the Localized Scleroderma Damage Index stayed essentially unchanged, and durometer measurements were not significantly different after treatment. Fibrosis can soften, but scarred tissue does not simply reset on demand. That separation between activity and damage is exactly what one would expect from a modality that can quiet ongoing inflammation and remodel early sclerosis more readily than it can erase long-standing structural change.
The cohort suggests benefit, but the design keeps the signal provisional
The study was a single-arm, nonrandomized pilot with a single reviewer assessing baseline and post-treatment outcomes. Such a design can show directionality, but it cannot prove how much of the improvement came from UVA-1 itself, how much reflected regression to the mean, and how much was influenced by ongoing background therapy. The inclusion of three different disease entities also dilutes disease-specific inference. Morphea, systemic sclerosis, and chronic cutaneous GVHD share sclerosis as a phenotype, yet they do not behave identically at the bedside or in the dermis.
Still, the consistency across several domains is hard to dismiss. Patient-reported symptom burden eased. Skin activity scores dropped. Hand mobility improved. Emotional distress, which often tracks tightly with visible skin change and daily discomfort, also improved. For patients living with fibrosing skin disease, those are not abstract endpoints; they map directly onto pain, stiffness, self-image, and the mechanical difficulty of moving through a normal day.
Why UVA-1 remains biologically plausible for fibrosing skin disease
UVA-1 penetrates deeper into the dermis than many other phototherapy approaches, making it a plausible candidate for disorders characterized by dermal inflammation and collagen deposition. In sclerosing skin disease, the therapeutic target is not only redness or scale, but the fibrotic scaffold itself. If inflammation can be reduced early enough, the surrounding matrix may become less rigid, skin thickness may soften, and mobility may improve before scarring becomes entrenched.
That biological logic helps explain why activity scores moved while damage scores did not. It also explains why the response was strongest in outcomes tied to symptoms and clinician impression rather than in endpoints that capture irreversible tissue remodeling. The therapy may be most useful where sclerosis is still metabolically active, not where the disease has already frozen the dermis into a fixed state.
Small numbers leave the next questions wide open
The study closes with cautious optimism rather than certainty. Sample size was small, treatment was given alongside other immunomodulatory agents, and the mixed-disease cohort limits broader generalizability. No stratified analysis by antibody profile was performed, so potentially important biologic subgroups were not examined. The nonrandomized, nonblinded structure also leaves plenty of room for measurement bias.
Even so, these pilot data support continued study of UVA-1 phototherapy in sclerosing skin disease, especially in patients with active skin thickening, symptom burden, and functional limitation. The clearest unanswered issue is whether the same gains would hold in a controlled trial with disease-specific enrollment and longer follow-up. Until then, the most defensible conclusion is narrower: UVA-1 appears capable of improving symptoms and selected clinical measures of sclerosis, while established damage remains far more resistant to change.